Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Gilead Turns in Sweet Earnings Numbers
- Eben Tessari submits: Gilead GILD put up some pretty sweet numbers this quarter totally blowing away analyst expectations with both revenue and net income up over 25% each. Other high points included a gross profit margin of 84%, prompting some to make the claim that the era of...
- External links 2008-10-19
- BioMarin Rolls the Dice on a New Lupus Drug
- Eben Tessari submits: BioMarin Pharmaceutical BMRN and La Jolla Pharmaceutical Company announced that they have entered into an agreement to develop and commercialize Riquent®, La Jolla’s investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Following a...
- External links 2009-01-08
- Cubist and Alnylam, An Odd Partnership
- Eben Tessari submits: Cubist CBST and Alnylam ALNY have formed a strategic collaboration to develop and commercialize Alnylam’s ALN-RSV program. The RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients,...
- External links 2009-01-11
- Bristol-Myers Jumps Into Hepatitis C Race
- Eben Tessari submits: Bristol-Myers Squibb BMY has decided to jump into the hotter by the second race for hepatitis C therapies. BMS and ZymoGenetics have entered a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its...
- External links 2009-01-13
- 5 Reasons Pfizer Shouldn't Buy Wyeth
- Eben Tessari submits: Reasons to buy Wyeth WYE Misery loves company. Reasons not to buy Wyeth by Eben Tessari
- External links 2009-01-25
- Astellas Proposes to Acquire CV Therapeutics for $1Billion
- Eben Tessari submits: Astellas (ALPMF.PK) announced that it has submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash. The proposal represents a 41% premium to the closing share price of CV Therapeutics on...
- External links 2009-01-27
- Idenix and GSK Partner on HIV Treatment Drug
- Eben Tessari submits: Idenix IDIX and GlaxoSmithKline GSK announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.Terms Upfront: $34M ($17M in cash; $17M equity stake @ 6.87/share or ~17% premium to 30 day trailing ave) Milestones: $416M Royalties: Double digit tiered Development: GSK assumes all...
- External links 2009-02-06
- Lilly Taps NeuroSearch for Preclinical Discovery Deal
- Eben Tessari submits: Just a week after NeuroSearch failed a phase II pain trial (ABT-894), they’ve inked a collaboration which will focus on new CNS therapeutics based upon defined ion channel targets. NeuroSearch is eligible to receive equity payments and research funding of up to USD 30 million over the...
- External links 2009-02-18
- Astellas Announces Offer to Buy CV Therapeutics
- Eben Tessari submits: Astellas (ALPMF.PK) announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of CV Therapeutics CVTX at a price of US$16.00 per share. The offer and withdrawal rights are scheduled to expire at 12:01 a.m., New...
- External links 2009-03-02
- Vertex to Buy Hepatitis C Drug Developer ViroChem for $375 Million
- Eben Tessari submits: Vertex VRTX, which is developing the hepatitis C virus (HCV) protease inhibitor telaprevir, will add two polymerase inhibitors to its HCV drug development portfolio through an agreement to acquire privately-held ViroChem Pharma in a stock and cash transaction. The move expands Vertex’s global presence in HCV and...
- External links 2009-03-04
- Merck to Buy Schering-Plough in $41.1 Billion Cash and Stock Deal
- Eben Tessari submits: Not to be outdone by Pfizer PFE / Wyeth WYE, Merck MRK and Schering-Plough SGP announced that their Boards of Directors have unanimously approved a merger. Schering has a strong pipeline and was my best of breed to be acquired in the medium sized pharmaceutical space. I...
- External links 2009-03-09
- GlaxoSmithKline Allies With Dynavax to Target Autoimmune Diseases
- Eben Tessari submits: GlaxoSmithKline GSK and Dynavax DVAX announced a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. Dynavax’s lead inhibitor drug candidate, DV1079, is a bifunctional inhibitor of TLR7 and TLR9, and is expected to enter...
- External links 2008-12-17
- Ascent Enters $200M Pact With Novartis
- Eben Tessari submits: Ascent Therapeutics announced that it has entered into a licensing option agreement through the Novartis Option Fund. Ascent will discover and develop Pepducin drug candidates against a specific GPCR target. The agreement includes an upfront fee and potential milestones totaling over $200 million as well as...
- External links 2008-12-09
- Can MicroRNA Reverse Heart Disease?
- Eben Tessari submits: Regulus Therapeutics, a joint venture between Alnylam ALNY and Isis ISIS formed to discover, develop, and commercialize microRNA-based therapeutics, announced the publication of new research in the journal Nature on the role of a microRNA, known as miR-21, in heart failure. Apparently, this is the first...
- External links 2008-12-01
- Glaxo and AFFiRiS Sign Alzheimer?s Disease Vaccine Deal
- Eben Tessari submits: GlaxoSmithKline Biologicals GSK and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programs, aimed at treating Alzheimer’s by targeting beta-amyloid. As part of the agreement, GSK is acquiring exclusive rights to develop and commercialize two Alzheimer’s...
- External links 2008-10-30
- GlaxoSmithKline to Acquire Genelabs Technologies For $57M
- Eben Tessari submits: I’m a huge fan of early stage deals with lots of upside and a cost under $75M. GlaxoSmithKline, looking to shore up their hepatitis C pipeline, announced that they have entered into an agreement with Genelabs Technologies for approximately $57 million (£35 million) through a tender...
- External links 2008-10-31
- EMD Serono Snags US license for Tesamorelin From Theratechnologies
- Eben Tessari submits: Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...
- External links 2008-10-31
- Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal
- Eben Tessari submits: Genzyme GENZ announced that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult mesenchymal stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic...
- External links 2008-11-05
- Onyx's $320M Bet on BTG's Anticancer Compound
- Eben Tessari submits: BTG has granted the worldwide commercialization and development rights of BGC 945, a novel anticancer compound, to Onyx ONXX in exchange for a potential $320M. BGC 945 is a novel compound that inhibits thymidylate synthase (TS), an enzyme involved in cell growth and division. However,...
- External links 2008-11-10
- Will TorreyPines Sale of Its Alzheimer Genetics Research Save the Company?
- Eben Tessari submits: TorreyPines Therapeutics, Inc. TPTX Tuesday announced that it has agreed to sell its Alzheimer’s disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding...
- External links 2008-11-11
- << Previous
- page 1 of 2
- Next >>
